Amar Pandya, CFA, is the portfolio manager of the Pender Alternative Arbitrage Fund, Pender Alternative Arbitrage Plus Fund, Pender Alternative Special Situations Fund, and Pender Small/Mid Cap Dividend Fund. He joined the company in October 2017. He began his investment career in 2011 in the portfolio management training program at a large global financial services company. He moved to pursue his passion for equities becoming an associate portfolio manager at a large-cap equity value firm before joining Pender. As an advocate of a contrarian value investing approach, Pandya works to identify out-of-favor, high-quality compound growth businesses, as well as opportunistic close-the-discount investment opportunities trading at a significant discount to intrinsic value. He has also developed expertise in event-driven special situations with a primary focus on M&A and balance sheet-driven special situations. Top contributing special situations he has uncovered include Maxar Technologies, Bausch Health, MAV Beauty Brands, Alcanna, Corus Entertainment, and Athabasca Oil. Pandya holds a bachelor's of commerce degree in finance (honors) from the University of Manitoba. He earned his chartered financial analyst (CFA) designation in 2015. He is actively involved with CFA Society Vancouver where he serves on the CFA Vancouver Programs Committee. He also sits on the Steering Committee for the Vancouver chapter of Women in Capital Markets.
With wide spreads, an improved playbook for assessing deal risk, and the potential for more M&A activity to materialize, 2024 could be a strong year for merger arbitrage performance.
What is behind the M&A bonanza in La Belle Province?
Amid the current artificial intelligence (AI) hype cycle, the M&A playbook has changed.
Despite the global drought in M&A, bright spots remain — if you know where to look.
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.